SANUWAVE, Inc.'s dermaPACE Shown to Improve Skin Flap Survival

ALPHARETTA, Ga.--(BUSINESS WIRE)--SANUWAVE Health, Inc. (OTCBB: SNWV) today reported publication of peer-reviewed, preclinical data conducted at Heidelberg University Hospital, the largest medical center in Germany, that demonstrates the ability of the Company’s dermaPACE® technology to improve skin flap survival after a specific type of tissue injury known as ischemia-reperfusion (IR) injury. During IR injury, a period of low blood flow (ischemia) is followed by restoration of normal blood flow (reperfusion). This sequence of events is known to cause negative tissue effects, and it is often encountered clinically in many types of microsurgical procedures, including skin flaps and replantation surgery.

Back to news